GlassScriptPhysician profile
Se Young Han
NPI 1154652949
$4,324.33
in general payments reported to CMS, 2019-2025
48 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.33 · 2020: $11.08 · 2021: $181 · 2022: $413 · 2023: $1,059 · 2024: $1,535 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,495.16 |
| Education | $211.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $565.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $314.42 | 2023-2025 | |
| Mirati Therapeutics, INC. | $286.14 | 2023-2024 | Krazati |
| Daiichi Sankyo INC. | $256.07 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $227.15 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Abbvie INC. | $205.86 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.26 | 2021-2024 | Libtayo |
| Janssen Biotech, INC. | $164.74 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $157.72 | 2022-2025 | Keytruda, Lynparza |
| Seagen INC. | $149.97 | 2022-2024 | Tukysa |
| Glaxosmithkline, LLC. | $139.62 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $126.46 | 2023-2025 | Venclexta, Tecentriq, Itovebi |
| E.R. Squibb & Sons, L.L.C. | $117.22 | 2022-2025 | Opdivo, Eliquis, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $115.88 | 2021-2025 | |
| Amgen INC. | $104.19 | 2022-2023 | Vectibix, Nplate, Xgeva |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $94.72 | 2024-2025 | Ninlaro, Fruzaqla, Aralast |
| Exelixis INC. | $83.88 | 2022-2025 | Cabometyx |
| Taiho Oncology, INC. | $72.69 | 2022-2025 | |
| Incyte Corporation | $72.69 | 2023-2025 | Jakafi |
| Pharmacosmos Therapeutics INC. | $72.28 | 2023-2024 | Monoferric |
| Beigene USA, INC. | $69.46 | 2024-2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $65.32 | 2024-2025 | Ultomiris |
| Celgene Corporation | $49.12 | 2023-2025 | Reblozyl |
| Emd Serono, INC. | $44.06 | 2023-2025 | Bavencio |
| Rigel Pharmaceuticals, INC. | $42.27 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Corcept Therapeutics | $40.52 | 2025 | Korlym |
| Eisai INC. | $38.05 | 2024 | |
| Tersera Therapeutics LLC | $35.99 | 2023-2025 | Xermelo, Zoladex |
| Genmab U.S., INC. | $35.24 | 2022-2023 | Epkinly |
| Stemline Therapeutics INC. | $33.59 | 2025 | Orserdu |
| Geron Corporation | $31.39 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $31.03 | 2023-2024 | Besremi |
| Lilly USA, LLC | $29.50 | 2019-2024 | Jardiance |
| Axsome Therapeutics, INC. | $28.47 | 2023-2024 | Sunosi |
| Genzyme Corporation | $21.82 | 2024 | |
| Adaptive Biotechnologies Corporation | $21.46 | 2024 | Clonoseq |
| Array Biopharma INC | $21.04 | 2024 | Braftovi, Mektovi, Tukysa |
| Astellas Pharma US INC | $20.91 | 2025 | Vyloy |
| Jazz Pharmaceuticals INC. | $18.87 | 2025 | |
| Puma Biotechnology, INC. | $17.57 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.32 | 2024 | |
| Insulet Corporation | $15.13 | 2023 | Omnipod |
| Sobi, INC | $15.12 | 2024 | |
| Cti Biopharma Corp. | $14.57 | 2023 | Vonjo |
| Welch Allyn | $14.55 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.35 | 2022 | |
| Baxter Healthcare | $13.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Se Young Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.